Navigation Links
FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
Date:5/6/2011

MANHATTAN BEACH, Calif., May 6, 2011 /PRNewswire/ -- Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors.  Neuroendocrine tumors make up less than five percent of all pancreatic cancer diagnoses and are generally slower growing and less aggressive than the more common form of pancreatic cancer, pancreatic adenocarcinoma.

(Logo:  http://photos.prnewswire.com/prnh/20100914/MM64269)

"The FDA approval of Afinitor to treat pancreatic neuroendocrine tumors is welcome news for the pancreatic cancer community. For decades, treatment options for this insidious disease have been limited.  We are thrilled that patients with pancreatic neuroendocrine tumors now have another option when planning their course of treatment," stated Julie Fleshman, President and CEO of the Pancreatic Cancer Action Network.  

Afinitor® underwent rigorous clinical trials to determine the safety and effectiveness of the drug in this specific cancer type.  It was previously approved to treat other cancer types, but needed to prove effective in patients with pancreatic neuroendocrine tumors.  To this point, treatment options for pancreatic neuroendocrine tumors have not been well-established.  Patients have historically been treated with surgery, chemotherapies, and/or radiation.  In contrast to these treatment modalities, Afinitor® is a targeted therapy designed to attack specific proteins that are necessary for the growth of cancer cells.

"The Pancreatic Cancer Action Network encourages all patients to consider clinical trials when exploring treatment options. Clinical trials are a vital part of the research process and development of effective treatment options that will increase the survival rate of pancreatic cancer patie
'/>"/>

SOURCE Pancreatic Cancer Action Network
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 ... Nitrate Industry" and "2014 Deep Research Report on ... to its research database. Photo ... Deep Research Report on Global and China Potassium ... report on China and ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ) a ... delivery systems for the eye today reported revenue for ... million, a 10% increase over $18.2 million reported for ... basis, revenues grew 11% during the second quarter of ... effect of foreign currency exchange reduced sales by $0.1 ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2
... 1, 2011    Advanced Biologics, ( www.advancedbiologics.com ) ... newest product within the OsteoAMP ® platform ... meeting this week in Chicago, IL.  OsteoAMP Structural ... that demonstrates osteoinductive properties in-vivo.  Initial product offerings ...
... 2011 Merz Aesthetics, Inc., the exclusive distributor of ... launch of the "STAND AND DELIVER" program.  In partnership ... selected for their significant abilities to STAND AND DELIVER, ... a stand by making a difference in their communities. ...
Cached Medicine Technology:Advanced Biologics Launches OsteoAMP® Structural at the 26th Annual Meeting of the North American Spine Society 2Merz Aesthetics and Inspirational Women Join Forces to Recognize Women Who STAND AND DELIVER 2Merz Aesthetics and Inspirational Women Join Forces to Recognize Women Who STAND AND DELIVER 3
(Date:8/2/2014)... Arizona (PRWEB) August 02, 2014 ... the nation's number one provider of customized medical and ... two major dental-industry conferences this fall. CEDR’s CEO will ... in September and early December. , From September 4-6, ... Dental Office Managers (AADOM) Dental Managers Conference in San ...
(Date:8/1/2014)... 02, 2014 Recently, iFitDress.com, one of the ... new assortment of top bridesmaid dresses online. At ... promotional prices, up to 52% off. According to the company’s ... of August. , The company’s stock is limited. Those ... its online store as soon as possible. All its products ...
(Date:8/1/2014)... University School of Medicine in St. Louis helps explain ... frequently are more harmful than similar tumors in females. ... are diagnosed twice as often in males, who suffer ... as long. , The researchers found that retinoblastoma protein ... significantly less active in male brain cells than in ...
(Date:8/1/2014)... New York, New York (PRWEB) August 01, 2014 ... ) filed in the wake of the 2012 ... continue to move forward in New Jersey’s Bergen ... to documents filed in the proceeding, the Court ... Order of Confidentiality governing any and all hard ...
(Date:8/1/2014)... New York (PRWEB) August 01, 2014 ... ) on behalf of women who allegedly experienced the ... power morcellators in gynecological surgeries, Bernstein Liebhard LLP notes ... withdraw a number of power morcellators marketed by its ... report from The New York Times, some critics of ...
Breaking Medicine News(10 mins):Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 2Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 3Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4
... of Houston (UH) has invited best-selling author and noted physician ... in Family, Health and Human Values at 7:30 p.m., Monday, ... "As an Indian-American immigrant to the United States, Dr. ... inaugurate the new India studies program at UH," said Lois ...
... A UCSF study gives hope to those suffering from severe ... if left untreated. The use of topical corticosteroids in a ... harmful in the overall patient population in the study. However, ... corneal ulcers, according to UCSF researchers. In a paper ...
... , TUESDAY, Oct. 18 (HealthDay News) -- Colorectal cancers ... the cancer and could prove important in diagnosing, treating and ... the Dana-Farber Cancer Institute and the Broad Institute in Boston ... of colorectal cancer tissue and found unusually high numbers of ...
... HealthDay Reporter , MONDAY, Oct. 17 (HealthDay News) ... Pap tests as a cervical cancer screening tool among ... The U.S. Preventive Services Task Force published ... are now seeking to fine-tune these guidelines. The results ...
... -- Unstructured play is much better than TV or videos ... American Academy of Pediatrics policy statement says. Free play ... solve, and develop reasoning and motor skills at an early ... pediatric experts pointed out in an AAP news release. ...
... has found that coughing may signal trouble for patients with ... published in the journal Respirology , found that patients ... develop advanced forms of the disease that may be life ... the lungs becomes thick and scarred, likely due to a ...
Cached Medicine News:Health News:Dr. Abraham Verghese to give John P. McGovern Lecture on Oct. 24 2Health News:UCSF study finds steroids could help heal some corneal ulcers 2Health News:Link Explored Between Colon Cancer, Bacterium 2Health News:Pap Test Still Best for Cervical Cancer Screening, Experts Say 2Health News:Pap Test Still Best for Cervical Cancer Screening, Experts Say 3Health News:'Screen-Free' Play Best for Toddlers' Brains 2Health News:Cough may warn of danger for patients with lung-scarring disease 2
... has been designed for use with Bioneer's ... can handle 96 samples (Plasmid DNA, Genomic ... and purification. While conventional kits use centrifugal ... BioVac 96 Vacuum Manifold uses vacuum pressure ...
Plastic Tray Type Vacuum Manifold...
... manifold is designed to efficiently process ... holds one deep well plate and ... are drawn through the wells ... microplates. The base holds and ...
QIAvac 96 is designed for efficient processing of QIAGEN 96-well plates....
Medicine Products: